An agreement has been reached that will require the NHS to allocate an additional £3 billion for medications to satisfy demands made by Donald Trump. However, this move could result in more than 15,000 deaths due to the NHS having to limit other essential healthcare services, as cautioned by a leading expert.
The deal, aimed at increasing the NHS’s willingness to pay for new drugs, was primarily made to avoid tariffs imposed by the US President on UK pharmaceutical exports. Government officials argue that this agreement will enhance investments in the UK and provide patients with quicker access to state-of-the-art medicines.
Nevertheless, projections from the Centre for Health Economics at the University of York suggest that the increased spending on drugs could lead to loss of lives as it diverts funds that could have been used more efficiently on healthcare staff and equipment.
The center’s leading expert has warned that a rise in fatalities, particularly from cancers, heart attacks, and lung diseases, is anticipated. Professor Karl Claxton emphasized the detrimental impact of the government’s decision to raise drug payment rates on NHS patients, social care, and local economic growth.
According to Professor Claxton, the concessions made to increase drug payments could result in severe consequences, outweighing any benefits to the UK pharmaceutical sector from potential tariffs. The estimated additional cost to the NHS for drugs is £3 billion annually, though the total expense is expected to be higher.
Research spanning over a decade indicates that if the NHS covers the costs, there could be 15,971 additional deaths and a loss of 352,000 years of healthy life annually. Alternatively, if the Treasury shoulders the burden, the funds could have been directed towards the NHS, reducing mortality rates and enhancing health conditions.
The impact is projected to extend to a £66 million rise in social care expenses, potentially diminishing the quality of life for users and unpaid carers by at least 24,000 QALYs. Furthermore, local economic growth may suffer, leading to a GDP reduction ranging between £18 billion and £26 billion.
Historically, the NHS has been able to secure lower drug prices compared to private hospitals in the US, thanks to its collective bargaining power.
Threatened with substantial tariffs on drug imports, including those from UK firms, by Donald Trump, the NHS was compelled to comply with higher pricing demands. Several pharmaceutical companies also threatened to withdraw investments from the UK unless the government agreed to pay more.
The UK government has now consented to raise the maximum threshold for purchasing new medicines by 25%, increasing the likelihood of expensive new drugs being considered cost-effective by the National Institute for Health and Care Excellence (NICE).
Trade Secretary Peter Kyle stated that the agreement secures tariff-free entry of UK pharmaceutical exports worth a minimum of £5 billion annually into the US. Proponents of the deal, including government officials and medical leaders, highlight the approval of pricier, cutting-edge medications such as revolutionary cancer treatments.
<p class="Paragraph_paragraph-text__PVKlh" data-tmdatatrack="content-unit" data-tmdatatr